Nuwellis (NUWE) Stock Falls -58% in 30 Days on Dilution Pressure
Key Takeaways
- Nuwellis shares closed at $1.30 on August 13, 2026, down from $3.12 on July 15, 2026, a decline of approximately 58% over the last 30 days.
- The selloff was driven primarily by dilutive capital-raising activity, including a registered direct offering priced at $2.59 per share on July 31, 2026, and warrant exercise proceeds.
- Second-quarter 2026 results showed operational progress, with revenue rising 14% year over year and gross margin reaching 76%, but the improving fundamentals did not offset financing-related pressure.
- The broader quarterly trend is steeper: on a split-adjusted basis, NUWE fell roughly 96% from about $35.70 on May 14, 2026, to $1.30 on August 13, 2026.
- Investors continue to watch cash runway, pediatric label expansion, recurring Aquadex utilization, and the potential for additional dilution.
Nuwellis (NUWE) Business Overview
Nuwellis, Inc. is a medical technology company focused on fluid management and cardiorenal care. The company develops, manufactures, and commercializes ultrafiltration therapy systems, including the Aquadex FlexFlow and Aquadex SmartFlow platforms. These systems are designed to remove excess fluid from patients with fluid overload who have not responded adequately to diuretic therapy, with indications covering adult and pediatric patients weighing 20 kilograms or more.
Nuwellis sells directly to hospitals and clinics in the United States and through specialty distributors in select international markets. The company is headquartered in Eden Prairie, Minnesota, and was formerly known as CHF Solutions before rebranding in 2021. Its strategy is centered on expanding Aquadex adoption in pediatric and critical care settings, improving recurring circuit utilization, and advancing complementary technologies such as the Clarity Prime kidney function monitoring system acquired through Rendiatech. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Stock Price Performance: 30 Days vs. Quarter
Over the last 30 days, NUWE moved from a closing price of $3.12 on July 15, 2026, to $1.30 on August 13, 2026. That represents a decline of approximately 58.3%. The move was not linear: shares experienced sharp volatility in late July, including a brief intraday spike to $6.40 on July 30 before closing at $4.45, followed by a gap lower after a subsequent financing announcement. The stock then drifted lower into mid-August, closing down 7.8% on August 13 after second-quarter earnings.
The quarterly performance has been considerably weaker. From a split-adjusted closing level of about $35.70 on May 14, 2026, NUWE fell to $1.30 on August 13, 2026, a decline of roughly 96%. The quarterly trend reflects sustained selling pressure tied to equity financings, a reverse stock split, and lingering uncertainty about cash needs, even as the company reported improved revenue growth and gross margin.
What Drove the Price Action in the Last 30 Days
The dominant catalyst over the last 30 days was dilutive financing. On July 31, 2026, Nuwellis announced a registered direct offering of 1,310,890 shares at $2.59 per share, generating approximately $3.4 million in gross proceeds. The company also received about $3.1 million from the exercise of previously issued warrants tied to its June 2026 public offering. The combination increased share supply and refocused investor attention on dilution risk, triggering a sharp repricing from the prior session's close of $4.45.
Fundamental news was comparatively constructive. On August 13, 2026, Nuwellis reported second-quarter revenue of $1.97 million, up 14% year over year, while U.S. revenue rose 17%. Gross margin improved to 76% from 56% in the prior-year quarter, and the company sold nine U.S. consoles compared with three a year earlier. Management stated that recent capital raises and warrant exercises extended the cash runway through the second quarter of 2027. Earlier in the period, the company announced a next-generation Aquadex platform strategy and strengthened its product development organization with a senior engineering appointment. Despite those operational updates, financing-related selling pressure dominated the tape. From what I see, this pattern aligns with similar small-cap medtech names that have faced repeated equity raises.
Quarterly Drivers and Market Reaction
The quarterly decline reflects a combination of capital structure stress, a corporate action, and operational transition. In early June, Nuwellis priced a $6 million public offering at $0.30 per share with warrants, a deeply discounted transaction that caused a sharp selloff. Later in June, the company completed a 1-for-35 reverse stock split as part of its effort to maintain Nasdaq listing compliance.
Operationally, the company made progress. A leadership transition took effect with Mike McCormick becoming CEO, and Nuwellis expanded pediatric programs in Michigan, Wisconsin, and South Carolina. The company also completed an FDA pre-submission meeting for a proposed Aquadex label expansion to patients weighing 5 kilograms and above, with a submission planned for the fourth quarter of 2026. Still, the market's primary concern remained the cost of funding operations, the size of warrant overhang, and whether revenue growth could reduce cash burn quickly enough. Those concerns outweighed the improving revenue and margin story over the quarter. I’m watching this closely as the company navigates its next regulatory steps.
Key Factors to Monitor Going Forward
The key factors to monitor include Nuwellis's ability to sustain double-digit revenue growth, maintain gross margin, expand the installed base of Aquadex consoles, and convert placements into recurring circuit utilization. Cash runway and future financing activity remain central risks, given the company's reliance on equity raises and outstanding warrants. The planned FDA submission for pediatric label expansion in the fourth quarter of 2026 represents a potentially important regulatory catalyst, while development progress on Clarity Prime and the next-generation Aquadex platform could shape the longer-term product story. Investors should also watch operating expense trends, Nasdaq listing compliance, and whether improved commercial execution translates into lower cash burn.
Using Tickeron’s AI Tools for Ongoing Research
In my own work, I turn to Tickeron’s Trending AI Robots page to review curated AI-driven trading strategies across different market conditions. It helps filter active bots by performance and timeframe without sifting through the full marketplace, providing a practical starting point when evaluating names like NUWE alongside broader sector trends. This approach keeps my analysis grounded in systematic signals while I focus on the fundamentals.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
NUWE's RSI Oscillator ascends from oversold territory
The RSI Oscillator for NUWE moved out of oversold territory on July 30, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 61 similar instances when the indicator left oversold territory. In of the 61 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 18 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 31, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NUWE as a result. In of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NUWE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
NUWE broke above its upper Bollinger Band on July 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NUWE entered a downward trend on July 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.182) is normal, around the industry mean (11.053). P/E Ratio (0.028) is within average values for comparable stocks, (73.178). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.988). NUWE has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (0.005) is also within normal values, averaging (31.009).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. NUWE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NUWE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of heart assist devices
Industry MedicalNursingServices
Advertisement